

## ATHEROGENIC INDICES IN CASES OF IDIOPATHIC PRETERM PREMATURE RUPTURE OF MEMBRANES AND HEALTHY PREGNANT CONTROLS: A COMPARATIVE STUDY

Shanmuga Priya <sup>1</sup>, Mohit Mehndiratta <sup>2</sup>, Edelbert Anthonio Almeida <sup>3</sup>,  
Amita Suneja <sup>4</sup>, Seema Garg <sup>5</sup>, Rajarshi Kar <sup>5</sup>

### Filiation:

<sup>1</sup> University of College of Medical Sciences, Department of Biochemistry, Post Graduate Student, Delhi, India

<sup>2</sup> University of College of Medical Sciences, Department of Biochemistry, Director Professor and Head, Delhi, India

<sup>3</sup> University of College of Medical Sciences, Department of Biochemistry, Senior Resident, Delhi, India

<sup>4</sup> University of College of Medical Sciences, Department of Obstetrics and Gynecology, Director Professor and Head, Delhi, India

<sup>5</sup> University of College of Medical Sciences, Department of Biochemistry, Professor, Delhi, India

**How to cite this article:** Priya S, Mehndiratta M, Almeida EA, Suneja A, Garg S, Kar R. Atherogenic Indices in cases of idiopathic preterm premature rupture of membranes and healthy pregnant controls: A Comparative Study. *Revista Internacional de Salud Materno Fetal*. 2025; 10 (4): o10-o17. DOI: 10.47784/rismf.2025.10.4.444

**Financing:** IMRG, UCMS

**Conflict of Interest:** None

### Corresponding Author:

Mohit Mehndiratta  
e-mail: drmohitucms@gmail.com

Received: 01-08-2025

Revised: 13-10-2025

Approved: 09-11-2025

Advanced: 19-11-2025

Published: 23-11-2025



### ABSTRACT

**Objective:** To evaluate and compare atherogenic indices in women with idiopathic Preterm Premature Rupture of Membranes (pPROM) and gestational age matched healthy pregnant controls. **Material and methods:** This cross-sectional study was done in the department of Biochemistry and Obstetrics and Gynecology of UCMS and GTBH, Delhi. The study comprised 60 participants: 30 women with idiopathic pPROM (26-34 weeks gestation) and 30 controls with uncomplicated pregnancies who were matched for gestational age. We computed the following atherogenic indices from lipid profile parameters: non-HDL-C, Lipoprotein Combined Index (LCI), LDL-C/HDL-C, TC/HDL-C, Atherogenic Coefficient (AC) and Atherogenic Index of Plasma (AIP) and analysed the data. **Results:** HDL-C levels were lower in idiopathic pPROM group. TC, TG, and LDL-C levels were higher in cases of idiopathic pPROM group. CRP levels were also higher in cases of idiopathic pPROM group, indicating increased systemic inflammation. All atherogenic indices except non-HDL-C were significantly elevated in the idiopathic pPROM group. **Conclusion:** Compared to healthy pregnant age-matched controls, women with idiopathic pPROM had a significantly pro-atherogenic lipid profile, elevated atherogenic indices and a higher inflammatory milieu. These findings also suggest a potential mechanism that links dyslipidaemia and proinflammatory state with membrane weakening that ultimately results in premature rupture of membranes. Thus, these women require closer monitoring for timely interventions to alleviate adverse outcomes.

**Key words:** Pregnancy, pPROM, Dyslipidaemia, Atherogenicity, Atherogenic Indices (*Source: MeSH, NLM*)

## INTRODUCTION

Pregnancy is a dynamic state wherein physiological changes occur in almost all the organ system to sustain the developing embryo. Metabolic pathways are no exception and undergo changes to sustain the energy demands of the growing embryo. These changes include increased levels of energy substrates such as circulating glucose and lipids. Literature has documented increase in circulating levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and phospholipid from the beginning of the 12th week of and they continue to increase throughout pregnancy.[1] These changes are linked to insulin resistance that is developed along with dyslipidaemia in pregnant women.

Dyslipidemia denotes a derangement in a patients fasting lipid profile characterized by low level of HDL-C with higher levels of LDL-C and TG. It is linked to an increased risk of atherogenicity and its associated sequelae. There are various studies that have explored the possible connection between maternal lipid levels and risk for adverse pregnancy outcomes. Vrijkotte TG et., 2012 reported that triglycerides concentration during early stages of pregnancy was linearly linked with the occurrence of pregnancy-induced HTN, pre-eclampsia, preterm birth (PTB).[2] Another study by Jelliffe-Pawlowski LL et al. (2014)[3] analysed 842 pregnant patients and reported a strong link between mid-trimester maternal dyslipidaemia and risk of PTB.[4] Increased levels of oxidized LDL-C in maternal plasma has also been linked to a greater risk of pre-eclampsia.[5]

Further highlighting the link between dyslipidemia and adverse pregnancy outcomes, CatovJ. M. et al. [6] reported higher serum levels of TC and TG in pregnant women at 8 weeks of GA who subsequently developed spontaneous preterm birth (sPTB) or pPROM; suggesting the role of dyslipidemia in adverse pregnancy outcomes even before maternal adaptations are fully established. Consequently, CatovJ.M. et al. [7] further reported that the risk of sPTB at <34 weeks was elevated when both inflammation and dyslipidemia were present before 21 weeks of gestation.

Dyslipidemia is intricately linked to endothelial dysfunction which is a precursor to atheroma formation.[8] In addition, inflammation and its resultant oxidative stress (OS) are also implicated in the development of an atheroma. sPTB and pPROM are known to be pro-inflammatory states by themselves with studies [9] documenting increased levels of inflammatory markers in these patients compared to healthy pregnant controls. Therefore, these women may be predisposed to increased atherogenicity and cardiovascular risk; however, there are no studies documenting the same. Atherogenic dyslipidemia is postulated to have a role in the cases of pPROM via promoting an environment rich in oxidizable lipids leading to excess generation of free radical which culminates in OS. It also promotes a state of low-grade inflammation which not only induces the expression of cytokines but also matrix metalloproteinases. Lastly it is linked with endothelial dysfunction which may adversely affect placental vascular health.

Atherogenic Indices (LDL-C/HDL-C, TC/HDL-C, non-HDL-C, Atherogenic coefficient, lipoprotein combined index and Atherogenic Index of Plasma): representing the pro-atherogenic apolipoproteins to anti-atherogenic lipoproteins levels were developed to optimize the predictive power of the lipid profile without increasing the cost of testing. They have been extensively studied and proven to be potent cardiovascular disease (CVD) risk markers in patients with CVD.

There is no study done till date that has compared the atherogenic indices in cases of idiopathic pPROM and healthy gestational age matched controls. Therefore, this study was designed to compare the atherogenic indices in cases of idiopathic pPROM and healthy gestational age matched controls.

## MATERIAL AND METHODS

This research study was done in department of Biochemistry in collaboration with department of Obstetrics and Gynaecology of a tertiary care center in accordance with the declaration of Helsinki from 01.08.2023 to 01.07.2024.

### Ethics statement

Ethical approval was promptly obtained from Institutional Ethics Committee-Human Research (IECHR-2023-59-25).

### Calculation of sample size

A detailed literature search yielded studies which compared lipid profile and atherogenic indices in spontaneous preterm birth and PROM. There were no studies comparing these parameters in idiopathic pPROM; therefore, this study can be considered as a pilot study. A convenient sampling of 30 participants per group was taken.

### Study participants

A total of 60 participants were recruited after obtaining written informed consent. Cases consisted of pregnant women between 26 and 34 weeks of gestation, diagnosed as idiopathic pPROM (n=30). We considered pPROM as the rupture of membranes earlier to 37/7 weeks of gestation. The diagnosis was confirmed by amniotic fluid pooling, ultrasound and positive Amnisure® dipstick test. Women with pPROM due to identifiable causes such as cervical insufficiency, uterine anomalies, polyhydramnios, prior history of interventions (e.g., amniocentesis, chorionic villus sampling) or prior history of pPROM or preterm birth, medical conditions (e.g., diabetes mellitus, hypertension, thyroid disorders, connective tissue or other diagnosed genetic disorder), inflammatory diseases, or infectious diseases or history of smoking during pregnancy were excluded.

Apparently healthy pregnant gestational age matched controls (26-34 weeks) were recruited from the antenatal clinic. Controls were assessed and followed uptill term to document any complications which might develop later in pregnancy. If any of the controls developed any pregnancy related complication, post recruitment, they were excluded and a fresh gestational aged, matched controls were recruited and the same procedure followed. This was done until 30 matched controls were recruited. Hence, participants with antepartum complications, including gestational diabetes mellitus, pregnancy-induced hypertension, antepartum hemorrhage, or pre-existing medical conditions (e.g., thyroid

disorders, heart disease, diabetes mellitus, hypertension), were excluded from the study. In both study groups, blood samples were collected at the time of recruitment (24-36 weeks).

Routine biochemical parameter and fasting lipid profile was performed on DXC 700 Autoanalyzer (Beckman Coulter) using company reagent packs via enzymatic method.

CRP was performed on Randox Imola Autoanalyzer by using company reagent packs via immunoturbidimetry method

Atherogenic Indices were calculated as follows:

- LDL-C to HDL-C Ratio =  $\frac{\text{LDL-C (mg/dL)}}{\text{HDL-C (mg/dL)}}$
- TC to HDL-C Ratio =  $\frac{\text{TC (mg/dL)}}{\text{HDL-C (mg/dL)}}$
- Non - HDL - C =  $\text{HDL-C (mg/dL)} - \text{HDL-C (mg/dL)}$
- Atherogenic Co-efficient =  $\frac{\text{Non-HDL-C (mg/dL)}}{\text{HDL-C (mg/dL)}}$
- Lipoprotein Combined Index =  $\frac{[\text{TC (mg/dL)} \times \text{TG (mg/dL)} \times \text{LDL-C (mg/dL)}]}{\text{HDL-C (mg/dL)}}$
- Atherogenic Index of Plasma =  $\text{Log} [\frac{\text{TG (mg/dL)}}{\text{HDL-C (mg/dL)}}]$  [10]

### Statistical Analysis

Data was analyzed using SPSS software Version 30 (SPSS Inc., USA) and data represented as Mean  $\pm$  SD. Normality of data was tested using the Kolmogrov-Smirnov test. Student's T test or Mann Whitney U test were used to compare different variables depending on the normality of the data. Correlation analysis was done using the Spearman rho correlation test. ROC (Receiver Operating Curve) and Multiple linear regression analysis were done. p value less than 0.05 were considered statistically significant.

## RESULTS

Data of 60 participants were analysed including 30 cases of idiopathic pPROM and 30 gestational age matched controls, who delivered normally at term. Kuppaswamy's scale was used for socio-economic status. All the participants were of lower or lower middle socio-economic status.

**Tabla 1.** Comparison of Lipid Profile between Idiopathic pPROM cases and healthy controls

Parameter (Mean ± SD)	Idiopathic pPROM (n=30)	Controls (n=30)	p value
Total Cholesterol (mg/dl)	243.70 ± 43.13	233.90 ± 65.04	0.494
Triglycerides (mg/dl)	243.17 ± 64.9	211.90 ± 77.19	0.264
High-Density Lipoprotein (mg/dl)	54.37 ± 12.91	63.60 ± 17.28	0.001
Low-Density Lipoprotein (mg/dl)	140.70 ± 41.92	127.92 ± 61.07	0.348

The mean age of patients in idiopathic pPROM group was 26.97 ± 4.35 years and that of the control group was 26.13 ± 4.22 years. The mean gestational age of patients in idiopathic pPROM group was 32.30 ± 1.84 weeks and that of the control group was 32.16 ± 1.63 weeks.

In this study, serum C reactive protein levels were higher in cases of idiopathic pPROM compared to gestational age matched controls (4.74 ± 2.58 vs 1.79 ± 1.61). Serum TC, TG and LDL-C levels were higher in the pPROM group compared to controls. HDL-C levels were lower in the pPROM group compared to the control group (Table 1).

Atherogenic indices i.e. LDL-C/HDL-C, TC/HDL-C, atherogenic coefficient, lipoprotein combined index and AIP were significantly higher in the idiopathic pPROM group compared to control group. Non-HDL-C level was higher in the idiopathic pPROM group. (Table 2)

In the present study, regression analysis demonstrated that in the subgroup labeled controls, the model showed moderate correlation (R = 0.532, R<sup>2</sup> = 0.283). Among the predictors, serum triglycerides (TG) exhibited a modest but statistically significant positive association with the period of gestation (B = 0.035, p = 0.040), whereas the atherogenic index of plasma (AIP) demonstrated a strong negative association with gestational duration (B = -22.455, p = 0.048). In contrast, the model for cases was not statistically significant (adjusted R<sup>2</sup> < 0; ANOVA: p = > 0.7), suggested that overall regression model does not significantly predict POG. Receiver operating characteristic (ROC) analysis revealed that Atherogenic indices (TC/HDL, AC, LCI, AIP) shows better discriminatory ability (AUC ~0.70-0.74) compared to conventional lipids (TCH, LDL, HDL).

**Tabla 2.** Comparison of Atherogenic Indices between Idiopathic pPROM cases and healthy controls

Parameter (Mean ± SD)	Idiopathic pPROM (n=30)	Gestational Age Matched Controls (n=30)	p Value
LDL-C / HDL-C	2.69 ± 0.96	2.02 ± 0.94	0.00001
TC / HDL-C	4.63 ± 1.04	3.78 ± 0.90	0.012
Non-HDL-C	189.33 ± 39.2	170.30 ± 54.97	0.120
Atherogenic Coefficient	3.63 ± 1.04	2.78 ± 0.90	0.0012
Lipoprotein Combined Index	160342.42 ± 76923.68	97237.50 ± 55910.89	0.0005
AIP	0.65 ± 0.16	0.51 ± 0.22	0.0115

LDL-C: Low-Density Lipoprotein-Cholesterol; HDL-C: High-Density Lipoprotein-Cholesterol; TG: Triglycerides; AIP: Atherogenic Index of Plasma

## DISCUSSION

Dyslipidaemia contributes to the generation of reactive oxygen species (ROS), which promote OS and systemic inflammation, thereby impairing endothelial function and contributing to atherogenicity. [11]

In our study, serum TC, serum TG and serum LDL-C levels were noted to be greater in patients with idiopathic pPROM than in the control group, while HDL-C levels were lower. Many trimester-specific reference intervals for lipid profiles during pregnancy have been proposed, which can help differentiate between physiological changes and potential pathological conditions. However, there is no universally accepted standard, and values can vary based on population, methodology, and regional factors.

Like our study, A.T. Ottun et al. [12] reported that higher levels of TC and LDL-C in cases of PTB (n=24) compared to those who delivered at term (n=212) while HDL-C and TG values were comparable in both groups. In their study, among 162 pregnant women (68.6%) who had hyperlipidaemia, 20 women (12.4%) experienced sPTB. Of the women who delivered preterm, 4 (16.7%) had normal lipid levels, while 20 (83.3%) had hyperlipidaemia involving one or more lipid subtypes. The difference in findings could be explained by the small sample size in the case group and from the fact they compared lipid profile done in cases at 14-18 weeks to that done in healthy controls at term. However, the association between spontaneous preterm delivery and hyperlipidaemia was not statistically significant in this cohort.

Vrijkotte et al. [2] also reported higher levels of TG and TC at 13 weeks of gestation in those women who later had PTB, compared to healthy controls, however the difference was not statistically significant. They further reported no association of serum TG and TC levels with pre-term delivery. Niyaty S et al. [13] reported 18 cases of PTB among 203 pregnant women. 10 cases among them were pPROM, out of which 8 cases of pPROM had a TG value of more than 150mg/dL while 9 cases had a TC value more than 200 mg/dL. They reported no cases of pPROM with HDL-C levels less than 50 mg/dl. However, the lipid profile was estimated between 24 and 28 weeks of gestation.

Smith CJ et al [4] reported that dyslipidaemia was significantly associated with increased odds of preterm birth. Further they established an associated risk for the development of other subcategories of preterm birth, including pPROM. There is still a limited literature available on the association between dyslipidaemia and sPTB, and none studying the relation of atherogenic indices with pPROM.

Atherogenic indices have been proven to have better predictive power than traditional lipid profile.[14] In our study, the atherogenic indices (LDL-C/HDL-C and TC/HDL-C ratios) were higher among cases of pPROM compared to healthy controls. It is like a study done by Bartha JL,[15]in Spain which studied their levels in PTB, and gestational age matched healthy controls. In that study, the mean gestational age at sample collection was  $31.27 \pm 2.14$  for cases of PTB and  $31.56 \pm 3.14$  for controls. In our study Atherogenic Coefficient, Lipoprotien Combined Index and AIP were higher among cases of idiopathic pPROM than in the gestational age matched controls. There are no studies which have compared the levels of Atherogenic Coefficient, Lipoprotien Combined Index and AIP in cases of idiopathic pPROM. These parameters have been shown to be associated with increased cardiovascular risk in other diseases. In addition, AIP, being a log-transformed value of ratio of TG to HDL-C, is considered a composite index exhibiting greater sensitivity than individual lipid indices.[16]

However, our study also observed that triglycerides had a positive association with gestational age in the control subgroup, contrary to several previous reports that linked hypertriglyceridemia with preterm birth. This discrepancy might be explained by differences in gestational timing of sample collection, subgroup characteristics, or collinearity among lipid predictors. Notably, the SPSS output indicated multicollinearity ("tolerance = 0.000"), reflecting the mathematical interdependence of lipid ratios. Multicollinearity may inflate standard errors, thereby affect regression coefficients and reduce model stability. Thus, while our results support an association between composite atherogenic indices and gestational duration, these findings should be interpreted with caution.

Inflammation and OS are linked to both PTB and increased risk of atherogenicity. Inflammation is both a trigger and perpetuator of cardiovascular disease by contributing to plaque instability, endothelial dysfunction and thrombogenesis. In this study we also recorded higher levels of CRP in cases of idiopathic pPROM compared to gestational age matched controls signifying a greater inflammatory insult. However, maternal serum CRP levels were measured only at the time admission, and no analysis of its longitudinal progression until delivery was done. Bartha JL. [15] suggested that greater inflammatory insult increases the risk of cardio-vascular disease in future, as inflammation is also a predicting factor for CVD.

Despite preterm delivery not being considered as a major risk factor of cardiovascular disease, the American Heart Association, in its 2011 guidelines, has recommended to consider history of adverse pregnancy outcomes including PTB during risk assessment for any cardiovascular risk in women.[17] The guidelines given by European Society of Cardiology, recommends periodic screening of women with history of PTB for hypertension and diabetes.[18] The need for such guidelines was further validated when a meta-analysis done by Wu P et al.[19] on 3,38,007 women showed an increased risk of future adverse cardiovascular outcomes in women with history of PTB.

Another interesting aspect which needs to be explored is the role of dyslipidemia in the pathogenesis of PTB or pPROM. Studies done till date have reported placental oxidation of maternal lipids. Oxidized lipids and inflammatory mediators stimulate placental trophoblast cells to produce additional pro-oxidant and pro-inflammatory signals, creating a self-perpetuating, feed-forward cycle of OS. [20,21] This persistent oxidative environment might lead to degradation of the extracellular matrix, weakening of fetal membranes, and ultimately increase the risk of sPTB or pPROM.

A primary limitation of this study was its small sample size. We did not adjust for potential confounders such as body mass index and physical activity. In addition, levels of apoproteins (ApoA and ApoB) and neonatal outcomes were not assessed. Studies with comprehensive data on potential con-

founders on a larger set of sample size are needed to confirm and expand upon the current findings.

This is the first study to document based on deranged Atherogenic indices in cases of idiopathic pPROM compared to gestational age matched controls. Follow up studies with larger sample size on the pattern of lipid profile and its association with adverse pregnancy outcome, beginning from the first trimester, would be needed to better our understanding. In addition, there is need of evidence-based guidelines for the treatment of dyslipidemia during pregnancy.

## CONCLUSION

Our findings hint at the presence of a pro-atherogenic environment in patients with idiopathic pPROM compared to gestational age matched controls. These results underscore the importance of monitoring lipid parameters particularly Atherogenic indices rather than simple lipid profile during pregnancy to identify pregnant women who are at a risk for developing pPROM and other adverse pregnancy outcomes. Close monitoring of these women might be beneficial. In addition, the question of whether these changes in maternal lipid parameters contributes to membrane weakening requires additional investigation.

## ACKNOWLEDGEMENT

This study was funded by the Intra Mural Research Grant (University College of Medical Sciences 2023).

## REFERENCIAS BIBLIOGRAFICAS

1. Jin WY, Lin SL, Hou RL, Chen XY, Han T, Jin Y, et al. Associations between maternal lipid profile and pregnancy complications and perinatal outcomes: a population-based study from China. *BMC Pregnancy Childbirth*. 2016; 16:60. doi: 10.1186/s12884-016-0852-9.
2. Vrijkotte TG, Krukziener N, Hutten BA, Vollebregt KC, van Eijdsden M, Twickler MB. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. *J Clin Endocrinol Metab*. 2012;97(11):3917-25. doi: 10.1210/jc.2012-1295. PMID: 22933545.
3. Jelliffe-Pawlowski LL, Ryckman KK, Bedell B, O'Brodovich HM, Gould JB, Lyell DJ, et al. Combined elevated midpregnancy tumor necrosis

- factor alpha and hyperlipidemia in pregnancies resulting in early preterm birth. *American journal of obstetrics and gynecology*. 2014;211(2): 141.e1–9.
4. Smith CJ, Baer RJ, Oltman SP, Breheny PJ, Bao W, Robinson JG, et al. Maternal dyslipidemia and risk for preterm birth. *PLoS One*. 2018;13(12): e0209579. doi: 10.1371/journal.pone.0209579.
  5. Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. *Am J Epidemiol*. 2014;180(4):346–58. doi: 10.1093/aje/kwu145.
  6. Catov JM, Bodnar LM, Kip KE, Hubel C, Ness RB, Harger G, et al. Early pregnancy lipid concentrations and spontaneous preterm birth. *American Journal of Obstetrics and Gynecology*. 2007; 197(6): 610.e1–610.e7. doi:10.1016/j.ajog.2007.04.024
  7. Catov JM, Bodnar LM, Ness RB, Barron SJ, Roberts JM. Inflammation and Dyslipidemia Related to Risk of Spontaneous Preterm Birth. *American Journal of Epidemiology*. 2007; 166(11): 1312–1319. doi:10.1093/aje/kwm273
  8. Singh M, Pathak MS, Paul A. A Study on Atherogenic Indices of Pregnancy Induced Hypertension Patients as Compared to Normal Pregnant Women. *J Clin Diagn Res*. 2015;9(7): BC05-8. doi: 10.7860/JCDR/2015/13505.6241.
  9. Shobokshi A, Shaarawy M. Maternal serum and amniotic fluid cytokines in patients with preterm premature rupture of membranes with and without intrauterine infection. *International Journal of Gynecology & Obstetrics*. 2002;79(3):209-15.
  10. Dobiášová M. AIP--aterogenní index plazmyjakovýznamný prediktorkardiovas kulárníhorizika: od výzkumu do praxe [AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice]. *Vnitr Lek*. 2006;52(1):64-71. Czech. PMID: 16526201.
  11. Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in overweight adults. *Obesity*. 2006; 14(12): 2127–2131.
  12. Ottun AT, Odunsi MA, Jinadu FO, Olumodeji AM, Tijani F, Olalere HF, et al. Maternal hyperlipidemia and spontaneous preterm delivery: a multi-centre cohort study. *J Matern Fetal Neonatal Med*. 2022;35(25):8530-8535. doi: 10.1080/14767058.2021.1988071.
  13. Niyaty S, Moghaddam-Banaem L, Sourinejad H, Mokhlesi S. Are maternal metabolic syndrome and lipid profile associated with preterm delivery and preterm premature rupture of membranes? *Arch Gynecol Obstet*. 2021;303(1):113-119.
  14. Zhu L, Lu Z, Zhu L, Ouyang X, Yang Y, He W, et al. Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people. *Kardiol Pol*, 2015;73:931–938. doi: 10.5603/KP.a2015.0086.
  15. Bartha JL, Fernández-Deudero A, Bugatto F, Fajardo-Exposito MA, González-González N, Hervías-Vivancos B. Inflammation and Cardiovascular Risk in Women with Preterm Labor. *Journal of Women's Health*. 2012; 21(6): 643–648. doi:10.1089/jwh.2011.3013
  16. Kammar-García A, López-Moreno P, Hernández-Hernández ME, Ortiz-Bueno AM, Martínez-Montaña MLC. Atherogenic index of plasma as a marker of cardiovascular risk factors in Mexicans aged 18 to 22 years. *Proc (BaylUniv Med Cent)*. 2020;34(1):22-27. doi: 10.1080/08998280.2020.1799479.
  17. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. *Circulation*. 2011;123(11):1243-62. doi: 10.1161/CIR.0b013e31820faaf8. Epub 2011. Erratum in: *Circulation*. 2011 Jun 7;123(22):e624.
  18. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice: Developed with the special contribution of the EACPR. *Eur J Prev Cardiol*. 2016;23(11):NP1-NP96. doi: 10.1177/2047487316653709.
  19. Wu P, Gulati M, Kwok CS, Wong CW, Narain A, O'Brien S et al. Preterm Delivery and Future Risk of Maternal Cardiovascular Disease: A Systematic Review and Meta-Analysis. *J Am Heart Assoc*. 2018;7(2): e007809. doi: 10.1161/JAHA.117.007809.
  20. Al-Gubory KH, Fowler PA, Garrel C. The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes. *Int J Biochem Cell Biol*. 2010;42(10):1634-50. doi: 10.1016/j.biocel.2010.06.001.
  21. Cotechini T, Graham CH. Aberrant maternal inflammation as a cause of pregnancy complications: A potential therapeutic target? *Placenta*. 2015;36(8):960-6. doi: 10.1016/j.placenta.2015.05.016

**Authors Contribution:**

**Shanmuga Priya** : Concept, design, definition of intellectual content, literature search, clinical studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing.

**Edelbert Anthonio Almeida**: Concept, design, definition of intellectual content, literature search, clinical studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing.

**Mohit Mehndiratta**: Concept, design, definition of intellectual content, literature search, clinical studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing and manuscript review.

**Amita Suneja**: Concept, design, definition of intellectual content, literature search, clinical studies, data acquisition, data analysis and manuscript review.

**Seema Garg**: Concept, design, definition of intellectual content, literature search, clinical studies, data acquisition, data analysis and manuscript review.

**Rajarshi Kar**: Concept, design, definition of intellectual content, clinical studies, data analysis, statistical analysis, manuscript editing and manuscript review.

The manuscript has been read and approved by all the authors, the requirements for authorship as stated earlier in this document have been met, each author believes that the manuscript represents honest work.